New Acetylcholinesterase Inhibitors for Alzheimer's Disease

Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Mona, Adem, Abdu, Sabbagh, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246720/
https://www.ncbi.nlm.nih.gov/pubmed/22216416
http://dx.doi.org/10.1155/2012/728983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246720/
https://www.ncbi.nlm.nih.gov/pubmed/22216416
http://dx.doi.org/10.1155/2012/728983

Ejemplares similares